SRT 1460

Research use only, not for human use.

SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM.

SRT1460 is a potent, selective SIRT1 activator with EC1.5 of 2.9 uM, displays good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 uM) and is more potent than Resveratrol; improves insulin sensitivity, lowers plasma glucose, and increases mitochondrial capacity in obese mice model.

Cell Viability Assay Cell Line:Patu8988t (pancreatic cancer cells), Panc-1 (pancreatic cancer cells), SU86.86 (pancreatic cancer cells), HPDE cellsConcentration:2 μM, 4 μM, 6 μM Incubation Time:72 hours Result:Inhibited cell viability in a dose-dependent manner, with all pancreatic cancer cells being more sensitive than the control HPDE cell. The IC50s of those cells were: Patu8988t, 1.62±0.13 μM; SU86.86, 2.31±0.23 μM; Panc-1, 0.66 ±0.02 μM; HPDE, 2.39±0.29 μM.Western Blot AnalysisCell Line:Patu8988t cells Concentration:5 μM Incubation Time:16 hours Result:SRT1460 increased expression of the autophagy marker LC3-II.

——

SRT1460

Chromatin/Epigenetic

Sirtuin

Sirtuin

——

——

925432-73-1

507.609

C26H29N5O4S

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (19.70 mM)

O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=CC(OC)=C(OC)C(OC)=C5

3,4,5-Trimethoxy-N-[2-[3-(1-piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]benzamide

(-20℃)

With Ice Pack

≥ 2 years